ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today provided a business update and reported financial results for the three and nine months ended September 30, 2025.

Business Update

• Completed private placement of up to $14.4 million. On October 23, 2025, the Company closed a private investment in public equity (PIPE) financing led by institutional investors. The PIPE generated gross proceeds of approximately $4.9 million before placement agent fees and expenses, with the potential for up to an additional $9.5 million in future proceeds through warrant exercises.
• Launched strategic initiative to enhance balance sheet flexibility. As previously announced by the Company on October 23 and November 13 of this year, ENDRA launched a strategic initiative designed to strengthen the Company’s long-term financial sustainability. As part of this initiative, ENDRA deployed a portion of its capital into an institutional grade reward-generating program supported by leading advisers and custodial partners. This program is structured to generate consistent, non-dilutive financial returns, while enhancing balance sheet flexibility and providing supplemental financial resources to support ENDRA’s operational and commercial objectives.
• Regained Nasdaq compliance. With the completion of the October PIPE financing, the Company regained compliance with Nasdaq’s minimum stockholders’ equity requirement (Rule 5550(b)(1)), resolving the previously disclosed deficiency.
• Completed single site clinical feasibility study of TAEUS^® Liver. ENDRA confirms that it will soon release key results from its recently completed clinical feasibility study evaluating the performance of the 2025 redesigned TAEUS^® device. The study assessed TAEUS^®’s ability to measure liver fat content, a key biomarker for diagnosing and monitoring MASLD and MASH versus the industry’s gold standard, Magnetic Resonance Imaging (MRI-PDFF) test.

“We’re at a transformative inflection point,” said Alexander Tokman, ENDRA’s Chief Executive Officer. “We have advanced on two critical fronts: financial sustainability for ENDRA and clinical validation for TAEUS^®. The recent successful private placement along with our new treasury strategy have created a non-dilutive value engine that enhances our financial strength. By reducing costs and fortifying the balance sheet, we are laying the groundwork for efficient commercialization of our life-saving TAEUS^® technology.”

Third Quarter 2025 Financial Results

For the third quarter of 2025, the Company’s cash burn from operations decreased 30% to $1.2 million compared with $1.7 million in the same quarter of 2024, reflecting cost-optimization initiatives including streamlined staffing, reduced overhead and a leaner operating model.

Total operating expenses for the third quarter of 2025 were $1.4 million compared with $1.5 million a year ago, reflecting the impact of cost-optimization measures partially offset by capital raising expenses.

As of September 30, 2025, ENDRA had $0.8 million in cash and cash equivalents. Subsequent to the quarter end, ENDRA raised $4.9 million in gross proceeds through a private placement.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (“TAEUS^®”), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS^® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section of our website, www.endrainc.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements—based on certain assumptions and describing our future plans, strategies, and expectations—can generally be identified by the use of terms such as “approximate,” “anticipate,” “attempt,” “believe,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “hope,” “intend,” “may,” “plan,” “possible,” “potential,” “project,” “seek,” “should,” “will,” “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are express differently. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.

Applicable risks and uncertainties include, among others: the results of the proposed offering; expectations regarding our treasury strategy and our ability to execute it successfully; our limited commercial experience, limited cash resources, and history of losses; our ability to obtain adequate financing to fund operations in the future; risks related to shifts in regulatory, accounting, or tax treatment affecting our treasury activities; the potential impact of any changes in financial reporting requirements; the risk that our stock price may be affected by the performance or valuation of assets held in our treasury; a determination that we are an investment company under the Investment Company Act of 1940; our ability to achieve profitability; delays or changes in regulatory requirements, policies, or guidelines; potential delays in submitting required regulatory applications or other submissions to, or receiving approvals from, the U.S. Food and Drug Administration (“FDA”) or other regulatory agencies; our ability to obtain and maintain required CE mark certifications and secured required FDA and other governmental approvals for our Thermo Acoustic Enhanced Ultrasound (“TAEUS^®”) applications; our ability to develop commercially viable products based on our TAEUS^® technology; market acceptance of our technology; the effect of macroeconomic conditions on our business; results of human studies, which may be negative or inconclusive; our ability to secure and maintain development partners; reliance on third parties, collaborations, strategic alliances, and licensing arrangements; the competitive landscape in the healthcare industry; our ability to protect our intellectual property; changes in healthcare industry practices or reimbursement policies; our ability to comply with regulations from federal, state, local, and foreign governmental agencies; our ability to maintain compliance with Nasdaq listing standards; our dependence on key members of management; and other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

You should not rely on forward-looking statements as predictions of future events. Forward-looking statements in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update such statements to reflect actual results or changes in expectations, except as required by law.

ENDRA Life Sciences Inc.
Condensed Consolidated Balance Sheets
	September 30, 2025				December 31, 2024
	(Unaudited)
Assets
Current Assets
Cash	$	794,036			$	3,229,480
Prepaid expenses		254,673				204,185
Total Current Assets		1,048,709				3,433,665
Non-Current Assets
Fixed assets, net		52,633				69,281
Right of use assets		491,363				578,013
Prepaid expenses, long term		365,417				365,417
Other assets		5,986				5,986
Total Assets	$	1,964,108			$	4,452,362
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable and accrued liabilities	$	671,516			$	508,293
Lease liabilities, current portion		128,791				96,937
Total Current Liabilities		800,307				605,230
Long Term Debt
Lease liabilities		396,537				487,482
Warrant Liability		595,884				799,284
Total Long Term Debt		992,421				1,286,766
Total Liabilities		1,792,728				1,891,996
Stockholders’ Equity
Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 17.488 and 17.488 shares issued and outstanding, respectively		-				-
Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; no shares issued and outstanding		-				-
Series C Preferred Stock, $0.0001 par value; 100,000 shares authorized; no shares issued and outstanding		-				-
Common stock, $0.0001 par value; 20,000,000 shares authorized; 786,902 and 536,908 shares issued and outstanding, respectively		77				53
Additional paid in capital		107,467,603				105,998,412
Stock payable		-				-
Accumulated deficit		(107,296,300	)			(103,438,099	)
Total Stockholders’ Equity		171,380				2,560,366
Total Liabilities and Stockholders’ Equity	$	1,964,108			$	4,452,362

ENDRA Life Sciences Inc.
Condensed Consolidated Statement of Operations
(Unaudited)
	Three Months Ended				Three Months Ended				Nine Months Ended				Nine Months Ended
	September 30,				September 30,				September 30,				September 30,
	2025				2024				2025				2024
Operating Expenses
Research and development	$	432,113			$	794,444			$	1,341,859			$	2,552,336
Sales and marketing		45,285				83,157				183,110				484,769
General and administrative		893,305				631,413				2,616,106				3,483,303
Total operating expenses		1,370,703				1,509,014				4,141,075				6,520,408
Operating loss		(1,370,703	)			(1,509,014	)			(4,141,075	)			(6,520,408	)
Other Income (Expenses)
Other income (expense)		42,018				65,528				79,474				72,069
Warrant expense		-				(7,323,685	)			-				(7,323,685	)
Changes in fair value of warrant liability		(267,274	)			3,341,829				203,400				3,341,829
Gain or Loss on settlement of warrant exercise		-				3,071,252				-				3,071,252
Total other income (expenses)		(225,256	)			(845,076	)			282,874				(838,535	)
Loss from operations before income taxes		(1,595,959	)			(2,354,090	)			(3,858,201	)			(7,358,943	)
Provision for income taxes		-				-				-				-
Net Loss	$	(1,595,959	)		$	(2,354,090	)		$	(3,858,201	)		$	(7,358,943	)
Net loss per share – basic and diluted	$	(2.10	)		$	(9.54	)		$	(5.68	)		$	(82.14	)
Weighted average common shares – basic and diluted		761,218				246,816				679,210				89,592

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251117008793/en/

Company Contact:

Investor Relations

investors@endrainc.com

www.endrainc.com



Investor Relations Contact:

Yvonne Briggs

Alliance Advisors IR

(310) 691-7100

ybriggs@allianceadvisors.com

Source: ENDRA Life Sciences Inc.